Eli Lilly & Co. (LLY)

128.30
NYSE : Health Technology
Prev Close 128.31
Day Low/High 127.43 / 129.48
52 Wk Low/High 74.51 / 130.75
Avg Volume 16.48M
Exchange NYSE
Shares Outstanding 1.04B
Market Cap 132.85B
EPS 3.10
P/E Ratio 40.99
Div & Yield 2.58 (1.82%)

Latest News

Lilly Announces Final Results Of Elanco Exchange Offer

Lilly Announces Final Results Of Elanco Exchange Offer

INDIANAPOLIS, March 13, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the final results of its offer for shareholders to exchange their shares of Lilly common stock for shares of Elanco Animal Health Incorporated (NYSE: ELAN)...

Lilly's CYRAMZA® (ramucirumab) Phase 3 RELAY Trial Met Primary Endpoint, Significantly Improving Progression-Free Survival In First-Line Treatment Of Patients With Metastatic EGFR-Mutated Non-Small Cell Lung Cancer

Lilly's CYRAMZA® (ramucirumab) Phase 3 RELAY Trial Met Primary Endpoint, Significantly Improving Progression-Free Survival In First-Line Treatment Of Patients With Metastatic EGFR-Mutated Non-Small Cell Lung Cancer

Global, randomized, placebo-controlled study confirms CYRAMZA, in combination with erlotinib, significantly delayed disease progression in previously untreated patients with metastatic non-small cell lung cancer whose tumors have activating EGFR mutations

Lilly Announces Preliminary Results Of Elanco Exchange Offer

Lilly Announces Preliminary Results Of Elanco Exchange Offer

INDIANAPOLIS, March 11, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that, based on preliminary results, its previously-announced offer for shareholders to exchange their shares of Lilly common stock for shares of Elanco Animal...

Lilly To Participate In Barclays Global Healthcare Conference

Lilly To Participate In Barclays Global Healthcare Conference

INDIANAPOLIS, March 8, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in the Barclays Global Healthcare Conference on Wednesday, March 13, 2019.

Lilly To Participate In Cowen Health Care Conference

Lilly To Participate In Cowen Health Care Conference

INDIANAPOLIS, March 7, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in the Cowen and Company 39 th Annual Health Care Conference on Monday, March 11, 2019.

Activists Aim to Eliminate Dual Role for Allergan CEO Saunders

Activists Aim to Eliminate Dual Role for Allergan CEO Saunders

David Tepper's Appaloosa LP renews calls for changes at the top.

Lilly Announces Final Exchange Ratio Of 4.5121 For Elanco Exchange Offer

Lilly Announces Final Exchange Ratio Of 4.5121 For Elanco Exchange Offer

INDIANAPOLIS, March 7, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the final exchange ratio for its previously-announced offer for shareholders to exchange their shares of Lilly common stock for shares of Elanco Animal Health...

Lilly Receives FDA Priority Review Designation For Emgality® (galcanezumab-gnlm) Injection For The Preventive Treatment Of Episodic Cluster Headache In Adults

Lilly Receives FDA Priority Review Designation For Emgality® (galcanezumab-gnlm) Injection For The Preventive Treatment Of Episodic Cluster Headache In Adults

INDIANAPOLIS, March 5, 2019 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) announced today that the U.

Eli Lilly Stock Drops After Launching Cheaper Version of Top-Selling Insulin

Eli Lilly Stock Drops After Launching Cheaper Version of Top-Selling Insulin

Eli Lilly shares traded lower Monday after it said it plans to launch a cut-price version of its top selling insulin treatment Humalog as pressure to lower drug costs continues to ripple through the pharmaceutical industry.

Lilly To Introduce Lower-Priced Insulin

Lilly To Introduce Lower-Priced Insulin

Authorized generic version of Humalog will be available in U.S. pharmacies at 50 percent lower list price

Lilly To Present Data Demonstrating Continued Scientific Advancements In Broad Dermatology Portfolio At AAD Annual Meeting

Lilly To Present Data Demonstrating Continued Scientific Advancements In Broad Dermatology Portfolio At AAD Annual Meeting

- Over 25 abstracts for medicines in Lilly's dermatology portfolio, including Taltz® (ixekizumab), highlight new findings for the treatment of patients with moderate-to-severe plaque psoriasis, including genital psoriasis and active psoriatic arthritis -

The Ones That Got Away: Cramer's 'Mad Money' Recap (Thursday 2/28/19)

The Ones That Got Away: Cramer's 'Mad Money' Recap (Thursday 2/28/19)

Jim Cramer lists the great stocks and the obvious winners he wishes he had talked about more.

Jim Cramer: How to Win Now, With or Without China

Jim Cramer: How to Win Now, With or Without China

If we can advance without China then who the heck knows where we can go with it.

Pfizer And Lilly Announce Top-line Results From Phase 3 Study Of Tanezumab In Chronic Low Back Pain

Pfizer And Lilly Announce Top-line Results From Phase 3 Study Of Tanezumab In Chronic Low Back Pain

NEW YORK and INDIANAPOLIS, Feb. 19, 2019 /PRNewswire/ -- Pfizer Inc.

3 Pet Product Stocks Ready to Be Unleashed: Dogness, Elanco and Zoetis

3 Pet Product Stocks Ready to Be Unleashed: Dogness, Elanco and Zoetis

Pets can bring significant profits to companies that cater to this niche market.

Hagens Berman: Judge Denies Insulin Makers' Motion To Dismiss Class-Action Lawsuit Regarding Skyrocketing Insulin Prices

Hagens Berman: Judge Denies Insulin Makers' Motion To Dismiss Class-Action Lawsuit Regarding Skyrocketing Insulin Prices

Today, a federal judge's opinion has greenlighted a national class-action lawsuit filed against Sanofi, Novo Nordisk and Eli Lilly for their systematic overpricing of insulin and concealment of a behind-the-scenes arrangement orchestrated to hike insulin...

Lilly Completes Acquisition Of Loxo Oncology

Lilly Completes Acquisition Of Loxo Oncology

INDIANAPOLIS, Feb. 15, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of Loxo Oncology, Inc.

Lilly To Participate In Leerink Partners Global Healthcare Conference

Lilly To Participate In Leerink Partners Global Healthcare Conference

INDIANAPOLIS, Feb. 14, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the Leerink Partners Global Healthcare Conference on Wednesday, February 27, 2019.

Boehringer Ingelheim And Lilly Announce The CAROLINA® Cardiovascular Outcome Trial Of Tradjenta® Met Its Primary Endpoint Of Non-inferiority Compared With Glimepiride

Boehringer Ingelheim And Lilly Announce The CAROLINA® Cardiovascular Outcome Trial Of Tradjenta® Met Its Primary Endpoint Of Non-inferiority Compared With Glimepiride

- Tradjenta (linagliptin) demonstrated no increased cardiovascular risk compared with glimepiride in adults with type 2 diabetes and cardiovascular risk

How to Fatten Up Your Portfolio By Investing in the Obesity Epidemic

How to Fatten Up Your Portfolio By Investing in the Obesity Epidemic

As the U.S. and the world grow fatter, some investors are seeing green as they bulk up on stocks of companies on the front-lines of this 21st century Battle of the Bulge.

Lilly To Participate In Guggenheim Healthcare Talks Idea Forum

Lilly To Participate In Guggenheim Healthcare Talks Idea Forum

INDIANAPOLIS, Feb. 8, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in the Guggenheim Healthcare Talks Idea Forum on Thursday, February 14, 2019.

Lilly Will Initiate Divestiture Of Its Remaining Interest In Elanco Animal Health

Lilly Will Initiate Divestiture Of Its Remaining Interest In Elanco Animal Health

Provides Lilly shareholders opportunity for tax-free exchange

Stocks End Lower as Wall Street Gets No Boost From State of the Union

Stocks End Lower as Wall Street Gets No Boost From State of the Union

Stocks ended lower Wednesday as investors found little in Donald Trump's State of the Union address to warrant extending recent market gains.

Eli Lilly Misses Q4 Earnings, Cuts 2019 Outlook After Loxo Oncology Deal

Eli Lilly Misses Q4 Earnings, Cuts 2019 Outlook After Loxo Oncology Deal

Eli Lilly posted weaker-than-expected fourth quarter earnings Tuesday, and lowered its 2019 profit guidance to reflect the impact of its planned acquisition of Loxo Oncology.

Small-Caps Are Making Big Moves in This Technically Extended Market

Small-Caps Are Making Big Moves in This Technically Extended Market

Focus on individual stock picking, and take a look at small-caps, as earnings season continues.

Donald Trump, China Trade, Disney, Snap and GM - 5 Things You Must Know

Donald Trump, China Trade, Disney, Snap and GM - 5 Things You Must Know

U.S. stock futures mixed as investors remain worried the U.S. and China could fail to reach a trade agreement following Donald Trump's State of the Union address; Walt Disney rises as earnings beat estimates but expenses could rise from the company's new digital offerings; Snap soars as losses narrow and its user growth stabilizes.

Take Some Profits on This Strength: Market Recon

Take Some Profits on This Strength: Market Recon

The market can still go higher, but the time has come for the slope of price discovery to normalize a bit.

Lilly Reports Strong Fourth-Quarter And Full-Year 2018 Financial Results, Lowers 2019 EPS Guidance To Reflect The Pending Acquisition Of Loxo Oncology

Lilly Reports Strong Fourth-Quarter And Full-Year 2018 Financial Results, Lowers 2019 EPS Guidance To Reflect The Pending Acquisition Of Loxo Oncology

- Fourth-quarter 2018 revenue increased 5 percent, driven by increased demand for newer medicines, while operating expenses increased 1 percent. Full-year 2018 revenue increased 7 percent to $24.556 billion.

TheStreet Quant Rating: B+ (Buy)